The National Pharmaceutical Pricing Authority (NPPA) has set a price ceiling for 51 drug formulations, including linagliptin-metformin hydrochloride tablets, a combination drug used to treat high blood sugar levels caused by type 2 diabetes, and rosuvastatin-clopidogrel, a combination drug used to prevent heart attack and stroke.
The pricing body has set a retail price of Rs 8.97 for a 150-mg capsule of linagliptin (2.5 mg) and metformin hydrochloride (500 mg) tablets.
Similarly, Rosuvastatin (20 mg) and clopidogrel (75 mg) are both priced at Rs 18.95.
It may be recalled that The National Pharmaceutical Pricing Authority extended the ceiling price fixing for orthopaedic knee implants until September 15, 2024, to ensure affordability and prevent patient deception.
The NPPA has ordered that if the retail price of any formulations is not met, the manufacturer or marketing company will be liable to deposit the overcharged amount and interest accrued under the Drugs (Prices Control) Order 2013 and the Essential Commodities Act, 1955.